Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 10:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Cognitive Impairments Clear all
Active, not recruiting Not applicable Interventional

Neurophysiology Biomarkers of Cognitive Impairment Associated With Deep Brain Stimulation

NCT05933681
View directory record Official record
Conditions
Parkinson Disease
Interventions
Neural recordings and stimulation
Device
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
40 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 20, 2026 · Synced Sep 26, 2026, 10:47 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Measurement and Training of Dual-Task of Gait in Persons With Multiple Sclerosis

NCT03536299
View directory record Official record
Conditions
Multiple Sclerosis, Gait Disorders, Neurologic, Cognitive Impairment
Interventions
Dual-task gait, Single-task gait
Other
Lead sponsor
Texas Woman's University
Other
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 17, 2019 · Synced Sep 26, 2026, 10:47 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Neuroinflammation and Alzheimer's Pathology in POCD

NCT05378659
View directory record Official record
Conditions
Post-Operative Confusion, Neuroinflammatory Response, Alzheimer Disease
Interventions
Montreal Cognitive Assessment, Stroop Test, 4AT Delirium, Grooved Pegboard, NACC Cognitive Battery, ERP Testing, Blood Plasma and Serum sampling, Cerebral Spinal Fluid Sample
Behavioral · Diagnostic Test
Lead sponsor
University of Tennessee Graduate School of Medicine
Other
Eligibility
60 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 17, 2022 · Synced Sep 26, 2026, 10:47 PM EDT
Terminated Not applicable Interventional Results available

Napping, Sleep, Cognitive Decline and Risk of Alzheimer's Disease

NCT03256539
View directory record Official record
Conditions
Sleep, Alzheimer Disease, Cognitive Impairment, Aging, CBT
Interventions
Sleep intervention, Placebo intervention
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
65 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Sep 26, 2026, 10:47 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)

NCT04437511
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Donanemab, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
60 Years to 85 Years
Enrollment
1,736 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
185
States / cities
Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 146 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 26, 2026, 10:47 PM EDT
Active, not recruiting Not applicable Interventional

Critical Illness Myopathy as a Cause of Debilitating ICU-Acquired Weakness

NCT00937001
View directory record Official record
Conditions
Myopathy, Cognitive Impairment
Interventions
Biopsy/Ultrasound
Procedure
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 99 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 1, 2026 · Synced Sep 26, 2026, 10:47 PM EDT
Completed Phase 2 Interventional Results available

Oxytocin or Galantamine Versus Placebo for the Treatment of Negative Symptoms and Cognitive Impairments in Schizophrenia

NCT01012167
View directory record Official record
Conditions
Schizophrenia
Interventions
Oxytocin, Galantamine, Placebo-Oxytocin, Placebo-Galantamine
Drug · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 64 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
6
States / cities
Baltimore, Maryland • Catonsville, Maryland • Dundalk, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 11, 2022 · Synced Sep 26, 2026, 10:47 PM EDT
Completed Phase 2 Interventional Results available

Trial of Mesna to Prevent Doxorubicin-induced Plasma Protein Oxidation and Tumor Necrosis Factor Alpha (TNF-α) Release

NCT01205503
View directory record Official record
Conditions
Breast Cancer, Non-Hodgkin's Lymphoma
Interventions
Mesna, Saline, Doxorubicin, Cyclophosphamide
Drug
Lead sponsor
Mara Chambers
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Feb 23, 2016 · Synced Sep 26, 2026, 10:47 PM EDT
Completed Not applicable Interventional

Virtual Reality Based Balance Training in People With Mild Cognitive Impairment

NCT02214342
View directory record Official record
Conditions
Distorted; Balance, Motor Deficit, Cognitive Deficit
Interventions
Balance Training
Other
Lead sponsor
University of Arizona
Other
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Sun City, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 15, 2014 · Synced Sep 26, 2026, 10:47 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

1/2-Dopaminergic Dysfunction in Late-Life Depression (The D3 Study)

NCT04493320
View directory record Official record
Conditions
Depression, Cognitive Impairment, Gait Impairment
Interventions
Carbidopa/levodopa, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
60 Years and older
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 21, 2023 · Synced Sep 26, 2026, 10:47 PM EDT
Terminated Phase 1 Interventional

Safety Study of HPP854 in Subjects With Mild Cognitive Impairment or a Diagnosis of Mild Alzheimer's Disease

NCT01482013
View directory record Official record
Conditions
Mild Alzheimer's Disease, Mild Cognitive Impairment
Interventions
HPP854, Placebo
Drug
Lead sponsor
High Point Pharmaceuticals, LLC.
Industry
Eligibility
50 Years to 85 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
3
States / cities
Miami, Florida • Durham, North Carolina • High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 29, 2012 · Synced Sep 26, 2026, 10:47 PM EDT
Completed Phase 2Phase 3 Interventional

Galantamine for Cognitive Deficits in Schizophrenia

NCT00463879
View directory record Official record
Conditions
Schizophrenia
Interventions
Galantamine
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 11, 2007 · Synced Sep 26, 2026, 10:47 PM EDT
Completed Not applicable Interventional Results available

Recommendations and Alerting for Delirium Alleviation in Real-Time (RADAR)

NCT04007523
View directory record Official record
Conditions
Delirium
Interventions
Family Support System, HELP Support System
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
70 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 20, 2024 · Synced Sep 26, 2026, 10:47 PM EDT
Completed Not applicable Interventional

Effects of Memory Boot Camp on Brain Function in Adults With Symptoms of Mild Cognitive Impairment (MCI)

NCT04426162
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
Multi-domain Intervention
Other
Lead sponsor
Neurocore
Other
Eligibility
55 Years to 85 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
3
States / cities
Boca Raton, Florida • Palm Beach Gardens, Florida • Grandville, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 10, 2020 · Synced Sep 26, 2026, 10:47 PM EDT
Completed Phase 3 Interventional

Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy

NCT01714661
View directory record Official record
Conditions
Schizophrenia, Impaired Cognition
Interventions
EVP-6124, Placebo
Drug
Lead sponsor
FORUM Pharmaceuticals Inc
Industry
Eligibility
18 Years to 50 Years
Enrollment
753 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
38
States / cities
Tucson, Arizona • Anaheim, California • Bellflower, California + 35 more
Source: ClinicalTrials.gov public record
Updated May 2, 2016 · Synced Sep 26, 2026, 10:47 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Recurrence Markers, Cognitive Burden and Neurobiological Homeostasis in Late-Life Depression

NCT05331599
View directory record Official record
Conditions
Depression in Old Age, Recurrence, Cognitive Dysfunction
Interventions
Not listed
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
60 Years and older
Enrollment
210 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 3, 2025 · Synced Sep 26, 2026, 10:47 PM EDT
Recruiting Early Phase 1 Interventional

Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease

NCT04123314
View directory record Official record
Conditions
Depressive Symptoms, Depression, Alzheimer Disease, Mild Cognitive Impairment
Interventions
Psilocybin
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 26, 2026, 10:47 PM EDT
Completed Phase 2 Interventional Results available

A 2-Period Crossover Study of BPN14770 in Adults Males With Fragile X Syndrome

NCT03569631
View directory record Official record
Conditions
Fragile X Syndrome, FXS, Fra(X) Syndrome
Interventions
BPN14770, Placebo
Drug
Lead sponsor
Tetra Discovery Partners
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 18, 2024 · Synced Sep 26, 2026, 10:47 PM EDT
Completed Phase 1Phase 2 Interventional Results available

The Effect of Donepezil (Aricept(Registered Trademark)) on REM Sleep in Children With Autism

NCT00695136
View directory record Official record
Conditions
Autism, Cognition Disorder
Interventions
Donepezil hydrochloride, Increase REM sleep percentage
Drug · Behavioral
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
2 Years to 10 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 23, 2013 · Synced Sep 26, 2026, 10:47 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

ALIGN: Aligning Medications With What Matters Most (Demonstration)

NCT06335953
View directory record Official record
Conditions
Polypharmacy, Alzheimer's Disease and Related Dementias, Mild Cognitive Impairment
Interventions
Pharmacist-led deprescribing intervention
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
65 Years and older
Enrollment
474 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 26, 2026, 10:47 PM EDT
Active, not recruiting Not applicable Interventional

nCCR for Chemotherapy Related Cognitive Impairment Randomized Study

NCT05283629
View directory record Official record
Conditions
Chemo-brain, Chemotherapy-Related Cognitive Impairment
Interventions
Neuroplasticity-based Computerized Cognitive Remediation, Active Control Condition
Behavioral
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
35 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Sep 26, 2026, 10:47 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Metabolic Syndrome, Inflammation, and Risk of Cognitive Decline

NCT00099567
View directory record Official record
Conditions
Cognitive Decline
Interventions
Not listed
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
70 Years to 79 Years
Enrollment
2,632 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1997 – 2002
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 31, 2005 · Synced Sep 26, 2026, 10:47 PM EDT
Not listed No phase listed Observational

Microbiome Composition and Function Contributes to Cognitive Impairment and Neuroinflammation in Parkinson's Disease

NCT05419453
View directory record Official record
Conditions
Parkinson Disease
Interventions
Not listed
Lead sponsor
California State University, San Bernardino
Other
Eligibility
55 Years to 85 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
San Bernardino, California
Source: ClinicalTrials.gov public record
Updated Feb 7, 2024 · Synced Sep 26, 2026, 10:47 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluating the Efficacy of Cranial Electrotherapy Stimulation in Mitigating Anxiety-induced Cognitive Deficits

NCT04961112
View directory record Official record
Conditions
Anxiety, Cognitive Deficit
Interventions
Cranial Electrotherapy Stimulation, Sham Cranial Electrotherapy Stimulation
Device
Lead sponsor
Tufts University
Other
Eligibility
18 Years to 28 Years
Enrollment
124 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Medford, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 9, 2025 · Synced Sep 26, 2026, 10:47 PM EDT